

UC Irvine

UC Irvine Previously Published Works

Title

WITHDRAWN: Dual targeting of mitochondrial Lon peptidase 1 and chymotrypsin-like protease by small molecule BT317, as potential therapeutics in malignant astrocytomas

Permalink

<https://escholarship.org/uc/item/0qv3h32g>

Journal

bioRxiv, 4(05-02)

ISSN

2692-8205

Authors

Douglas, Christopher

Jain, Shashi

Lomeli, Naomi

et al.

Publication Date

2024-05-23

DOI

10.1101/2023.04.13.536816

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

1 **Discovery and Validation of Novel LonP1 and Proteasome Inhibitor in IDH1-R132H Malignant**
2 **Astrocytoma Models**

3 Christopher Douglas¹, Naomi Lomeli², Javier Lepe¹, Kaijun Di², Nitesh Kumar Nandwana⁵, Adil Shareef
4 Mohammed⁵, Thao Vu², James Pham², Maria Cristina Kenney³, Bhaskar Das^{4,5*}, Daniela A. Bota^{1,2,6*}

5 *1 Department of Pathology & Laboratory Medicine, University of California Irvine, Irvine, CA, USA (C.D.,*
6 *D.A.B.)*

7 *2 Department of Neurology, University of California Irvine, Irvine, CA, USA (K.D., N.L., T.V., J.P.)*

8 *3 Department of Ophthalmology Research, University of California Irvine, Irvine, CA, USA (M.C.K.)*

9 *4 Arnold & Marie Schwartz College of Pharmacy & Health Sciences, Long Island University – Brooklyn, NY,*
10 *USA (N.K.D, B.D.)*

11 *5 Department of Pharmacology, Long Island University – Brooklyn, NY, USA (B.D.)*

12 *6 Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA (D.A.B.)*

13

14 ***Co-Corresponding Authors:** Daniela A. Bota, M.D., Ph.D.
15 University of California Irvine, Sprague Hall B200,
16 Irvine, CA 92697-4475, USA
17 Phone: (949) 824-7377
18 Fax: 714-456-6894
19 Email: dbota@hs.uci.edu

20

21 Bhaskar Das, Ph.D.
22 Long Island University – Brooklyn, 75 DeKalb Avenue, HS-610,
23 Brooklyn, NY 11201-5497
24 Phone: (718) 488-1471
25 Fax: 718-780-4586
26 E-mail: Bhaskar.Das@liu.edu


27

28 **Funding:** This work was supported by the National Institute of Neurologic Diseases and Stroke Award
29 (NINDS/NIH) [NS109423] to DAB and BD. This work was also supported by the NINDS/NIH Award
30 [NS111303], the National Center for Advancing Translational Sciences (NCATS/NIH) Award [UL1
31 TR001414], the UCI American Cancer Society Institutional Grant [ACS/IRG – 98-279- 07], the Ruth L.
32 Kirschstein National Research Service T32 Award [2T32CA009054-41 (MPI)] and the UCI Cancer Center
33 Award [P30CA062203] from the National Cancer Institute to DAB. *The content is solely the responsibility*
34 *of the authors and does not necessarily represent the official views of the National Institutes of Health.*

35 **Conflict of Interest:** The authors have no conflicts of interest to disclose.

36 **Authorship Statement:** Conception and design of this work: DAB, BD, CD, KD, and NL. Inhibitor synthesis
37 and design: BD and NKD. Brain mass spectrometry measurements: Cyprotex and Biotechnology
38 Innovation and Optimization Center. Data collection, analysis, and interpretation: CD and DAB. All the
39 authors critically reviewed and approved the final manuscript.

40 **Manuscript Word Count:** Abstract: 249; Importance of Study: 144; Text: 6257; References: 1777; Figure
41 Legend: 558.



43

44 **Abstract**

45 Malignant astrocytomas are aggressive glioma tumors that have poor prognosis and limited treatments
 46 available following recurrence. These tumors are characterized by extensive hypoxia-induced,
 47 mitochondria-dependent changes such as glycolytic respiration, increased chymotrypsin-like (CT-L)
 48 proteasome activity, decreased apoptosis, and increased invasiveness. Mitochondrial Lon Peptidase 1
 49 (LonP1) is an ATP-dependent protease directly upregulated by hypoxia-inducible factor 1 alpha (HIF-1 α).
 50 Both LonP1 expression and CT-L proteasome activities are increased in gliomas and are associated with a
 51 high tumor grade and poor patient survival. Recently, dual LonP1 and CT-L inhibition has been found to
 52 exhibit synergy against multiple myeloma cancer lines.

53 We now report that dual LonP1 and CT-L inhibition has synergistic toxicity in IDH mutant astrocytoma
 54 when compared to IDH wildtype glioma, due to increased reactive oxygen species (ROS) generation and
 55 autophagy. A novel small molecule, BT317, was derived from coumarinic compound 4 (CC4) using
 56 structure-activity modeling and was found to inhibit both LonP1 and CT-L proteasome activity and
 57 subsequently induce ROS accumulation and autophagy-dependent cell death in high-grade IDH1 mutated
 58 astrocytoma lines. *In vitro*, BT317 also had enhanced synergy with the commonly used chemotherapeutic
 59 temozolomide (TMZ), which blocked BT317-induced autophagy. This novel dual inhibitor was selective to
 60 the tumor microenvironment and demonstrated therapeutic efficacy both as a single agent and in
 61 combination TMZ in IDH mutant astrocytoma models. We show that BT317, a dual LonP1, and CT-L
 62 proteasome inhibitor exhibited promising anti-tumor activity and could be a promising candidate for
 63 clinical translation in the space of IDH mutant malignant astrocytoma therapeutics.

64 Data Access Statement: Research data supporting this publication are as presented in the manuscript.

65 **Keywords:** IDH mutant astrocytoma, Glioblastoma, LonP1, CT-L proteasome, BT317

66 **Highlights**

- 67 1. The novel compound BT317 acts as a LonP1 and chymotrypsin-like proteasome inhibitor
- 68 2. LonP1 and CT-L proteasome inhibition drives ROS production in IDH mutant astrocytoma
- 69 3. LonP1 and CT-L proteasome inhibition drives autophagy in IDH mutant astrocytoma
- 70 4. BT317 shows blood-brain barrier permeability and has low normal tissue toxicity
- 71 5. BT317 synergizes with the first-line chemotherapy agent TMZ

72 **Importance of Study**

73 Malignant astrocytomas (IDH mutant astrocytomas grade 4 and IDH wildtype glioblastoma) have poor
74 clinical outcomes, and novel treatments are needed to limit recurrence and improve overall survival.
75 These tumors have a malignant phenotype that is mediated by altered mitochondrial metabolism and
76 adaptation to hypoxia. Here, we present evidence that the small-molecule inhibitor BT317, with a dual
77 Lon Peptidase 1 (LonP1) and chymotrypsin-like (CT-L) inhibition profile, can be effectively used to induce
78 increased ROS production and autophagy-dependent cell death in clinically relevant, IDH mutant
79 malignant astrocytoma, patient-derived orthotopic models. BT317 showed strong synergy with the
80 standard of care, temozolomide (TMZ), in the IDH mutant astrocytoma models. This could lead to the
81 development of dual LonP1 and CT-L proteasome inhibitors as novel therapeutic strategies for IDH mutant
82 astrocytoma and provide insight for future clinical translation studies in combination with the standard of
83 care.

84 **1. Introduction**

85 Malignant astrocytomas are one of the most aggressive primary and secondary brain tumors, with a three-
86 year expected survival rate following surgical resection, radiation, and chemotherapy. Recurrence is
87 certain after the initial treatment, and there is currently no proven therapy to significantly prolong survival
88 after tumor recurrence^{1,2}. The current standard of care, temozolomide (TMZ, temodar), an alkylating
89 agent, provides a median survival advantage of 2.5 months when added to surgery and radiation therapy³.
90 The use of Tumor-Treating Fields (TTFields, Optune) further increases this survival advantage by 4
91 months⁴. Despite significant efforts and numerous past and ongoing clinical trials utilizing small molecule
92 inhibitors such as the STAT3 inhibitor WP1066, EGFR inhibitors, Dopamine Receptor D2 antagonists
93 (ONC201), and new immunotherapy checkpoint inhibitor approaches such as pembrolizumab, nivolumab
94 and ipilimumab, the development of safe and efficacious therapies for malignant astrocytomas has been
95 slow. In the past 16 years, only three therapies (TMZ, bevacizumab, TTFields) have been approved for the
96 treatment of astrocytomas⁵. Thus, there is an urgent need to develop alternative therapeutic strategies.

97 Malignant astrocytomas are increasingly classified based on their genetic and epigenetic profiles⁶. Less
98 than 10% of grade 4 astrocytomas express isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations, which are
99 associated with an improved response to treatment and prognosis as compared with the IDH wildtype
100 tumors⁷. Based on these biologic and survival differences, the most recent WHO glioma classification
101 excludes tumors with an IDH mutation from being classified as GBM and refers to such tumors as
102 astrocytoma grade 4, IDH mutant⁸. Even though the presence of the IDH mutations predict a better

103 outcome, the survival of patients with grade 4 IDH mutated astrocytoma treated with the standard
104 therapy (radiation and TMZ) is still only 31 months⁹. The presence of the IDH mutation (>90% are IDH1-
105 R132H) can drive tumorigenesis¹⁰ at the cost of impairing the mitochondrial electron transport chain in
106 cellular mitochondria, increasing ROS production, and creating increased vulnerability to pro-oxidative
107 and apoptotic signals¹¹. Direct targeting of the IDH1 mutation using specific inhibitors has proven
108 successful in other malignancies, notably IDH1-mutant Acute myelogenous leukemia, but had limited
109 results in IDH1 mutant malignant astrocytoma, and there is a great need to develop more targeted
110 strategies for this tumor type.

111 The invasive phenotype of malignant astrocytomas is partly mediated by overexpression of the
112 transcriptional activator hypoxia-inducible factor 1 alpha (HIF-1 α). HIF-1 α contributes to the hypoxia-
113 driven maintenance of glioma stem cells (GSCs)¹² by supporting self-renewal¹³, angiogenesis¹⁴, increased
114 invasiveness¹⁵, and high levels of genetic instability. The latter contributes to tumor heterogeneity and
115 presents a major challenge in devising novel therapeutic strategies for its treatment¹⁶. There are hundreds
116 of gene targets in the HIF-1 α signaling pathway and the nuclear-encoded Lon Peptidase 1 (LonP1) is
117 directly upregulated by HIF-1 α ¹⁷. LonP1 is an ATP-dependent protease that regulates mitochondrial
118 homeostasis through three main functions: (1) proteolytic degradation of mitochondrial proteins¹⁷, (2)
119 protein chaperone¹⁸, and (3) mitochondrial DNA (mtDNA)-binding protein¹⁹. LonP1 overexpression is a
120 poor prognostic factor that promotes invasion and metastasis in multiple cancers, including colorectal²⁰,
121 melanoma²⁰ and oral cancer²¹. Our previous results showed that LonP1 is overexpressed in astrocytomas
122 and its elevated expression levels are associated with high tumor grade and poor survival²². Furthermore,
123 LonP1 knockdown in established human glioma lines, D-54 MG and U-251 MG, reduced cell viability under
124 normal conditions, and drastically impaired survival under hypoxic conditions²². This is concomitant with
125 a decrease in mitochondrial respiration. Notably, LonP1 pharmacological inhibition using the coumarinic
126 compound 4 (CC4)²³ inhibited glioma cell proliferation and synergistically enhanced the therapeutic
127 efficacy of TMZ, *in vitro*²².

128 There is difficulty in the generation of specific LonP1 inhibitors²³, which is attributable to its structural
129 similarities with other known proteases and the proteasome²⁴. Most LonP1 inhibitors exhibit dual
130 inhibition of LonP1 and the proteasome²³. Targeting specifically the chymotrypsin-like (CT-L) proteasome
131 activity may be beneficial, as it plays an important role in tumor cell survival²⁵ and treatment resistance²⁶.
132 Dual inhibition of LonP1 and the CT-L proteasome activity could be potentially beneficial as it could offer
133 additional therapeutic benefits compared with targeting either protease activity alone. Recent work in
134 multiple myeloma has demonstrated the strong synergy with LonP1 and CT-L proteasome inhibition²⁷,
135 using specific inhibitors previously shown to have no cross activity, and to target only LonP1, Bardoxolone
136 methyl (CDDO-ME)^{28,29}, and the CT-L proteasome activity, carfilzomib (CFZ)³⁰. Bortezomib (BTZ) exhibits
137 dual LonP1 and CT-L inhibition and possesses a boronic acid group that can transform into a boronate
138 ester when exposed to reactive oxygen species (ROS)³¹; however, it has poor blood-brain barrier (BBB)
139 permeability³². In the subcutaneous U-87 MG and U-251 MG glioma models, BTZ was found to sensitize
140 the glioma tumors to TMZ by suppressing FOXM1-mediated treatment resistance³³. This study did not use
141 patient-derived lines and resorted to using a subcutaneous model instead of an orthotopic xenograft
142 model. In this study, we present BT317, a derivative of CC4^{22,23} and a dual LonP1 and CT-L inhibitor. We
143 assessed its LonP1 protease and proteasome inhibition profiles. We then investigated the efficacy and
144 feasibility of the lead compound BT317 as a single agent and in combination with TMZ as a therapeutic

145 strategy for specifically IDH mutated malignant astrocytomas, including in two separate IDH1-R132H
146 patient-derived, orthotopic xenograft models.

147 **2. Methods**

148 **2.1. Ethics Statement**

149 All astrocytoma tumor specimens were collected under institutional review board approved protocols
150 from patients who underwent surgical tumor resection at the University of California Irvine Medical
151 Center. The neuropathological review was completed by a specialized neuropathologist. All patient-
152 derived samples were deidentified. All animal studies were performed in accordance with the guidelines
153 established by the Institutional Animal Care and Use Committee (IACUC) at the University of California
154 Irvine.

155 **2.2. Synthesis of small molecule BT317 and related compounds**

156 Synthesis of BT317 was initiated using compound **D** (methyl 6-chloro-2-oxo-2H-chromene-3-carboxylate)
157 (**Fig. 1A**). Compound **D** was then synthesized from Compound **A** using the outlined process by first adding
158 5-chlorosalicylaldehyde (**A**, 1.55 g, 10 mM) to CH₃CN (5 mL) in a 35 mL reaction tube. Dimethylmalonate
159 (**B**) (1.45 g, 11 mM) and ethyl piperidine-3-carboxylate (**C**) (15 mg, 10 mol%) in 15 mL of CH₃CN were added.
160 The resulting reaction mixture was stirred at room temperature for 24 h. After the evaporation of CH₃CN,
161 the crude reaction mixture was purified by silica gel chromatography to give a white solid **D** (1.6 g, 60%).
162 Basic hydrolysis of compound **D** was performed to produce Compound **E** acid (6-chloro-2-oxo-2H-
163 chromene-3-carboxylic acid). Acid synthesis was initiated by adding methyl 6-chloro-2-oxo-2H-chromene-
164 3-carboxylate **D** (1.0 g, 4.2 mM) in ethanol to sodium hydroxide (10% w/v in 20 mL ethanol). The mixture
165 was stirred under reflux for 24 h. After the completion of the reaction, the mixture was cooled to room
166 temperature and diluted with 10% HCl. The solid precipitated out and was isolated and washed with
167 water, yielding compound **E** (white solid, 80% yield). Using compound **E**, we further derivatized to amide
168 (**BT173**) using a simple amide coupling reaction in the presence of coupling reagents. The 6-chloro-2-oxo-
169 2H-chromene-3-carboxylic acid **E** (1.0 mM) was dissolved in dichloromethane (DCM) (3 mL) in a 35 mL
170 reaction tube. Then 4-hydroxy aniline (1.1 mM) and DCC (1.2 mM) were added. The resulting reaction
171 mixture was stirred at room temperature for 24 h. The reaction was then quenched with a saturated
172 aqueous NaOH solution and extracted with DCM (10 × 3 mL). The combined organic layers were dried
173 over Na₂SO₄ and then filtered. After evaporation of the organic solvent, the residue was purified by silica
174 gel chromatography to obtain BT317, 6-Chloro-N-(4-hydroxyphenyl)-2-oxo-2H-chromene-3-carboxamide
175 (**Fig. 1B**; white solid, 78% yield). The reagents used for the synthesis were purchased from Fisher Scientific.
176 The structure was confirmed by nuclear magnetic resonance (NMR) and proton, carbon, and mass
177 spectrometry, and the purity of the compound was determined by HPLC. The lead compound, BT317, was
178 evaluated using NMR as follows: ¹H NMR (500 MHz, DMSO-d₆) δ 10.44 (s, 1H), 9.43 (s, 1H), 8.87 (s, 1H),
179 8.16 (d, J = 2.5 Hz, 1H), 7.82 (dd, J = 8.8, 2.6 Hz, 1H), 7.61 (d, J = 8.9 Hz, 1H), 7.53 (d, J = 8.5 Hz, 2H), 6.78
180 (d, J = 8.4 Hz, 2H). ¹³C NMR (125 MHz, DMSO) δ 160.0, 158.8, 154.2, 152.4, 145.7, 134.2, 133.5, 129.5,
181 129.0, 121.6, 121.2, 119.9, 118.2, 115.3. HRMS (ESI) was calculated for C₁₆H₁₁ClNO₄ (M.W. = 316.0371)
182 and 316.0607 [M + H]⁺.

183

184 **2.3. Primary and Established Cell Lines**

185 *Primary Glioma/Astrocytoma Stem Cell Cultures (GSC)*

186 Patient-derived GSC were isolated from surgical astrocytoma samples in the laboratory of Dr. Daniela A.
187 Bota (DAB), using a previously established method³⁴. All GSC cultures were maintained as non-adherent
188 neurospheres in Neurobasal medium (Thermo Fisher; 12349015) supplemented with 20 µg/mL EGF
189 (Thermo Fisher; PHG0313), 20 µg/mL FGF (Thermo Fisher; PHG0023), B27 (Life Technologies; 12587010),
190 GlutaMAX (Thermo Fisher; 35050061), 5 mM sodium pyruvate (Thermo Fisher; 11360070), and antibiotics
191 (Thermo Fisher; 15070063, 15290018). The patient-derived GSC lines included DB70, DB76, DB77, DB81,
192 and 83MES. The patient-derived 83MES line was a kind gift from Dr. Ichiro Nakano at the University of
193 Alabama at Birmingham.

194 *Established Human Glioma Cell Lines*

195 Five established human glioma cell lines, U-251 MG, D-54 MG, and U-87 MG, and the pediatric CHLA-200,
196 were maintained in DMEM/F-12 medium (Corning; 10-090-CV) containing 292 µg/ml glutamine, 1%
197 penicillin/streptomycin (Thermo Fisher; 15070063), and 10% FBS (Invitrogen; 10371-029). All the cell
198 cultures were maintained at 37°C and 5% CO₂ in a humidified incubator.

199 *Normal Cell Lines*

200 The human mammary gland epithelial adherent non-tumorigenic cell line MCF-10A was maintained in
201 DMEM/F-12 medium containing 0.5 mg/mL hydrocortisone, 20 ng/mL hEGF, 100 ng/mL cholera toxin, 1%
202 penicillin/streptomycin, and 5% horse serum (Life Technologies; 26050-070). The human lung fibroblast
203 line HPF242 was maintained in DMEM/F-12 containing 10% FBS and 1% penicillin/streptomycin. All the
204 cell cultures were maintained at 37°C and 5% CO₂ in a humidified incubator. Unlisted reagents were
205 purchased from Sigma-Aldrich and Thermo Fisher Scientific.

206 **2.4. XTT Viability Assay**

207 All established and patient-derived astrocytoma cell lines were seeded at a density of 10,000 cells per well
208 in a 96-well plate (n = 4 replicates per condition). The following day, equal volumes of synthesized
209 inhibitors dissolved in DMSO were added to each well at the specified concentrations (0.1-1000 µM). For
210 the synergy experiments, BT317 was added at specified concentrations with a fixed and specified TMZ
211 concentration. After 72 h, 100 µL volume was removed from each well, and 75 µL of a pre-filtered solution
212 of 1 mg/mL XTT sodium salt (Alfa Aesar, 111072-31-2) and 20 µL/mL XTT activator (Trevigen, 4891-025-
213 02) dissolved in PBS (pH 7.4; Gibco; 10010-023) was added. After 4 h, the absorbance was measured at
214 490 nm using a SpectraMax Plus 384 microplate reader. GraphPad was then used to perform a log
215 transformation and generate a nonlinear regression curve to calculate IC₅₀ viability. The Biochemically
216 Intuitive Generalized Loewe Model (BIGL) was used to determine agonism or antagonism ([https://cran.r-](https://cran.r-project.org/web/packages/BIGL/)
217 [project.org/web/packages/BIGL](https://cran.r-project.org/web/packages/BIGL/))³⁵.

218 **2.5. Reactive Oxygen Species Assay**

219 The DB70 line was plated and incubated for 12 h prior to starting treatment. CellROX™ Orange Reagent
220 (Thermo Fisher, C10443) was then added at a working concentration of 5 µM for 30 minutes. After several
221 1X PBS washes, the cell samples were replated and then imaged using a 20X objective on a Keyence BZ-
222 X810 Widefield Microscope.

223 **2.6. Colony Forming Assay**

224 The DB70 line was treated for 24 h, then plated on 24-well PDL-coated plates for 10 days with partial
225 medium changes at days 4 and 7. Samples were fixed on day 10 with 4% paraformaldehyde for 30 minutes
226 prior to labeling with DAPI in 0.3% Triton 1X PBS. After additional 1X PBS washes, the plates were imaged
227 using a 4X objective on a Keyence BZ-X810 Widefield Microscope.

228 **2.7. Western Blotting**

229 Cell culture samples were exposed to BT317 for 1, 4, 8, and 72 h prior to lysis with RIPA lysis buffer
230 containing 1 mM PMSF, 1 mM Na₃VO₄, and a protease inhibitor cocktail (Sigma, P8340-1ML). The protein
231 concentration was standardized using the DC Protein Assay (Bio-Rad, 500-0114) with a SpectraMax Plus
232 384 microplate reader. A Precision Plus Protein Kaleidoscope™ ladder (Bio-Rad, 161-0375) and
233 approximately 20 µg of sample were loaded onto each well and run on a Mini Protean TGX Gel (Bio-Rad,
234 456-1046) before being transferred to an Immobilon Transfer Membrane (Millipore, IPVH08130). The
235 membranes were probed with the indicated primary antibodies and the appropriate secondary
236 antibodies. The primary and secondary antibodies used were 1:2000 LonP1 (Proteintech, 15440-1-AP),
237 1:1000 Aconitase2 (Abcam, ab71440), 1:1000 LC3B (Cell Signaling Technology, 2775S), FOXM1 (Millipore
238 Sigma, SAB1412254-100UG), C-MET (Fisher Scientific, MAB3729), TFAM (Fisher Scientific, PA5-80107)
239 1:2000 B-Actin (Novus Biologicals, NB600-501), 1:1000 p-AKT (Abcam, ab192623-100ul), 1:10,000 goat
240 anti-mouse IgG F(ab')₂ (Enzo Life Sciences, ADI-SAB-100-J), and 1:3,000 IgG (H+L) Goat anti-Rabbit HRP
241 (Invitrogen, 32460); these were used according to the manufacturer's recommendations and diluted in
242 TBST with 3% BSA. Chemiluminescence was visualized using Amersham™ ECL™ Prime western blotting
243 Detection Reagent (GE Healthcare, RPN2232) and imaged using an Azure c600 Molecular Imager. ImageJ
244 was used to align the bands, improve contrast (<20%), and normalize and quantify all bands.

245 **2.8. LonP1 Protease Activity Assay**

246 The total proteolytic activity of purified recombinant LonP1 (Abcam, ab160451) was analyzed using a
247 Pierce Fluorescent Protease Assay Kit (Thermo Scientific™, 23266). A mixture of 200 nM LonP1 and 10
248 mM MgCl₂ was prepared in BupH™ Tris-buffered saline. LonP1 inhibitors or vehicle (DMSO) were then
249 added, and the samples were incubated at 37°C for 1 h. Following this incubation, an equal volume of 0.04
250 mg/mL FITC-casein (Thermo Scientific™, 23267), 4 mM ATP (Thermo Fisher, R0441), and 10 mM MgCl₂
251 was added prior to measurement using a Biotek Synergy HT plate reader. Digestion of fluorescein-labeled
252 casein was assessed by measuring fluorescence with excitation and emission filters at 490 and 525 nm,
253 respectively.

254 **2.9. Proteasome Activity Assay**

255 Proteolytic activity was assessed using a Proteasome-Glo™ assay system (Promega, G8531), comprising
256 Proteasome-Glo™ Chymotrypsin-Like Assay (G8621), Proteasome-Glo™ Trypsin-Like Assay (G8621) and
257 Proteasome-Glo™ Caspase-Like Assay (G8621). The assay was performed according to the manufacturer's
258 instructions. Tissue samples were flash frozen and ground using a Dounce Homogenizer (Fisher, 50-194-
259 5205). Samples were then harvested in ice-cold lysis buffer composed of 50 mM HEPES (pH 7.4), 250 mM
260 sucrose, 5 mM MgCl₂, 0.5 mM DTT, and 40 mM KCl in deionized, sterile water. For D-54 MG, cells were
261 seeded at a density of 200,000 cells per well onto a 6-well plate and subsequently exposed to LonP1
262 inhibitors (BT317, BT395, BT397, and BT399) at the specified concentrations and endpoints. The lysates
263 were incubated on ice for 30 min and centrifuged at 14,000 rpm for 10 min at 4°C. The supernatants were
264 collected and mixed 1:1 with stabilizing buffer composed of 40 mM HEPES (pH 8.0), 1 mM EDTA, and 20%

265 glycerol in deionized, sterile water. The protein concentration was standardized using the DC Protein
266 Assay (Bio-Rad, 500-0114) with a SpectraMax Plus 384 microplate reader. Samples were then diluted with
267 ice-cold proteasome dilution buffer and plated in a black, clear, flat-bottom 96-well plate at a
268 concentration of 8 µg protein in 50 µL/well (n = 3-4 replicates/sample). The plates were placed on a plate
269 shaker at 300-500 rpm for 30 s, followed by incubation for 10-30 minutes incubation at room temperature.
270 Luminescence was read using a Biotek Synergy HT plate reader.

271 **2.10. BT317 and TMZ Administration and Maximum Tolerated Dose (MTD) Escalation**

272 BT317 and TMZ was reconstituted in DMSO to create a concentrated stock prior to further dilution in 500
273 µL 1XPBS to generate the correct dosage for intraperitoneal injection (i.p.) in 10-14 week-old Rag1 KO
274 immunodeficient mice (Jackson Laboratory, B6.129S7-Rag1^{tm1Mom}/J). Mice were monitored following
275 injection and the clinical score was determined based on activity, appearance, and body condition with a
276 maximum score of 3, which is necessary to define the MTD³⁶. Mass spectrometry was performed on flash-
277 frozen brains and tail vein blood draws by contract research organizations (Cyprotex and Biotechnology
278 Innovation and Optimization Center) to determine BT317 levels.

279 **2.11. Patient-derived Orthotopic Xenograft Model**

280 The patient-derived lines DB70, DB76, DB77 and 83MES were seeded into 3-dimensional organoids using
281 an established methodology³⁷. Upon full expansion, the organoids were dissociated, and 1,000-10,000
282 cells were intracranially implanted into the right frontal lobe of 10-14 week-old Rag1 KO immunodeficient
283 mice (Jackson Laboratory, B6.129S7-Rag1^{tm1Mom}/J). After 5 or 10 days, treatment was initiated as specified,
284 with intraperitoneal (i.p.) injections every other day for a total of 5 doses over a span of 5 or 10 days as
285 specified. Animals were observed daily and sacrificed upon observation of distress, including hemiparesis,
286 obtundation, hunchback, or weight loss of 20% from the maximum weight achieved.

287 **2.12. Quantitative Polymerase Chain Reaction Assay**

288 For each cell line, growth conditions were standardized and ~500,000 cells were collected and flash frozen.
289 Samples were then processed according to the Quick-RNA™ Miniprep Plus Kit (Zymo Research, R1057)
290 specifications to prepare pure RNA samples. These were used to generate cDNA samples using a two step
291 reverse transcriptase and polymerase chain reaction with PerfeCTa SYBR Green Supermix and transcript
292 appropriate primers. The primers used include: LONP1 (5'- ATGGAGGACGTCAAGAAACG-3', 5'-
293 GACGCTGAAGCGGAAGTACTC-3') and B-Actin Primer Set (Qiagen, QT00095431). After preparing master
294 mixes samples were prepared in quadruplicate in a 96-well Reaction Microplates (Fisher Scientific,
295 4346907) and measured following a standard qtPCR protocol with a QuantStudio 7 Real-Time PCR System.
296 Annealing temperature and length was optimized for each primer pair. Amplification was measured as
297 fluorescence in quadruplicate replicates and analyzed using QuantStudio 7 software.

298 **2.13. Statistical Analysis**

299 Data were analyzed using Student's t-test or log-rank (Mantel-Cox) test when appropriate. Data are
300 presented as mean ± standard error of the mean (SEM). Significance between groups is denoted by *P
301 <0.05, **P <0.01, ***P < 0.001. Data were analyzed using the GraphPad Prism 5.0 software (GraphPad
302 Software, La Jolla, CA, USA). For the XTT viability assays, raw data were processed using a log transform
303 and a dose-response inhibition nonlinear model to determine IC50 and standard error. The statistical
304 significance of the Kaplan-Meier survival curve was verified using the Mantel-Cox log-rank test.

305

306 Results

307 3.1 Dual LonP1 and Chymotrypsin-like Activity Exhibits Enhanced Synergy on IDH1 Mutant Malignant 308 Astrocytoma Patient Derived Lines and Induces Greater Autophagy as Compared with IDH Wildtype 309 Lines.

310 Previous findings suggested that dual LonP1 and chymotrypsin-like (CT-L) proteasome inhibition may be
311 an effective strategy for targeting cancer cells; however, the exact mechanism has not been validated.
312 Here, we demonstrated that the selective LonP1 inhibitor, CDDO-ME²⁸, and CT-L proteasome inhibitor,
313 Carfilzomib (CFZ)^{28,29}, have strong synergy in reducing viability of multiple patient-derived malignant
314 astrocytoma lines (**Fig. 1A**). Interestingly, the IDH1-mutant astrocytoma patient-derived lines DB70 and
315 DB76 are sensitive to CDDO-ME doses as low as 200 nM CDDO-ME with CFZ at 1 and 5 nM; however, this
316 combination has more limited activity against IDH wildtype DB77 and 83MES lines (e.g., >400 nM CDDO-
317 ME, **Fig. 1B**). In the DB70 line, CDDO-ME treatment (200 nM) increased levels of the autophagy marker,
318 LC3B-I³⁸, which is further increased by 3, 8, 1.5-fold with co-incubation of 5 nM CFZ at 1, 12 and 24 h,
319 respectively. In DB76, a 13, 1.5, 3-fold increase was observed in LC3B-I at 1, 12 and 24 h, respectively. CFZ
320 alone did not alter LC3B-I levels (**Fig. 1C**). Furthermore, a significant increase in reactive oxygen species
321 (by ~50%) is observed after 12 h of 200 nM CDDO-ME and 5 nM CFZ treatment (**Fig. 1D**) as opposed to
322 either CFZ or CDDO-ME separately. However, none of the aforementioned treatments resulted in an
323 increase in ROS in the 83MES line.

324

325 3.2. Structure Activity Relationship Modeling for Developing CC4 Derivatives.

326 Our previous work with CC4 demonstrated that LonP1 inhibition could inhibit astrocytoma cell growth,
327 adaptation to hypoxic conditions, and increase the anti-tumor efficacy of TMZ²². Coumarinic compounds
328 have been found to exhibit high hepatotoxicity³⁹. To decrease off-target toxicity and improve anti-tumor
329 efficacy, we derived four novel LonP1 inhibitors from CC4 using structure-activity relationship (SAR)
330 modeling. A library of small molecules (e.g., BT395, BT397, BT399, and BT317) was identified *in silico*,
331 using customized computational protein structure modeling programs M4T, MMM, Mutate, and SAR with
332 Autodock4, Surflex-Dock, ICM, PESD, and SFC (B. Das, unpublished data). The CC4 ester group was
333 modified to develop peptidomimetic compounds (amides and oxadiazoles) with increased water
334 solubility. As a part of our rational design study, rings **A**, **B** and **C** were modified (**Fig. 2A**). Finally, the
335 hydrophobic portion of rings **A** and **B** was replaced with quinolinolin-2 (1H)-1 to improve solubility (**Fig.**
336 **2B**; BT317). We developed also developed a library of additional CC4 derivatives; as shown in
337 **Supplementary Fig. 2**. In Ring **A**, the benzyl group is prone to oxidation *in vivo* by oxidative cytochrome
338 enzymes to form acidic chloride, which is associated with high toxicity. Therefore, chlorine was directly
339 substituted at position 6 of the ring. The hydroxyl group on ring **C** was converted to a boronic ester group.
340 The boronic acid and potassium salts of trifluoroborate and acid isosteres are known to increase cell
341 permeability and reduce toxicity⁴⁰. Furthermore, boronic acid and ester-based prodrugs were used as
342 templates for ring **C** because boronic acid is selective for H₂O₂³¹.

343

344 **3.3. Novel CC4 Derivative, BT317, Exhibits On-Target Inhibition of LonP1 Protease and Proteasome**
345 **Activity**

346 Using our structure-activity relationship modeling approach, we derived BT317, BT395, BT397 and BT399
347 from CC4 and evaluated their relative LonP1 and proteasome inhibition profiles. To evaluate the on-target
348 inhibition potency of these compounds, we assessed LonP1 protease activity inhibition using a FITC-casein
349 assay (**Fig. 3A and Supplementary Fig. 3A**). BT317 demonstrated LonP1 protease inhibition with an $IC_{50}=56$
350 μM , while BT397 exhibited similar inhibition with an $IC_{50}=58 \mu\text{M}$. The other inhibitors showed no inhibition
351 of LonP1 protease activity (data not shown). Since most LonP1 inhibitors exhibit dual inhibition of LonP1
352 and proteasome²³, we next examined whether the compounds also inhibit the 20S proteasome. For this
353 assay, we prepared extracts from the established malignant glioma cell line, D-54 MG (**Fig. 3B**). At 10 μM ,
354 BT317 yielded a ~98 and 96% reduction in CT-L activity, a ~26% and 27% reduction in trypsin-like (T-L)
355 activity, and a ~23% and 30% reduction in caspase-like (C-L) activity at both 1 and 4 h, respectively. The
356 proteasomal activity of all three complexes returned to baseline at 8 h post-treatment. The BT395, BT397
357 and BT399 compounds showed limited inhibition of proteasome activity (**Supplementary Fig. 3C**). The
358 antioxidant N-acetyl cysteine (NAC) inhibits the production of ROS and is a known blocker of proteasome
359 inhibitors⁴¹. BT317 proteasome inhibition was eliminated by 10 mM NAC co-treatment.

360 In contrast to the other tested compounds, BT317 demonstrated quicker kinetic inhibition of CT-L
361 proteasome activity than BTZ (**Fig. 3B**), which is a potent dual LonP1 and CT-L proteasome inhibitor
362 approved for the treatment of multiple myeloma⁴². The observed CT-L inhibition by BTZ demonstrates
363 limited inhibition by comparison to BT317. Given the potent on-target LonP1 protease inhibition of BT317
364 and its accelerated CT-L proteasome inhibition, we selected BT317 for further evaluation as a dual
365 LonP1/proteasome targeted therapy in our astrocytoma models.

366 The mitochondrial matrix protein aconitase (Aco2) is the most important protease substrate for LonP1⁴³.
367 To evaluate the effect of BT317 on LonP1 substrate levels, we treated the established IDH wildtype D-54
368 MG and U-87 MG glioma lines with 10 μM BT317, well below the expected LonP1 protease inhibition
369 concentration, $IC_{50} = 56.03 \mu\text{M}$ (**Fig. 3C**). The D-54 MG line responded with a pronounced Aco2 protein
370 level increase of 2-fold at 1 h; however, this was quickly reversed by 8 and 24 h. TFAM was still elevated
371 by 3-fold at 24 h. We also compared this result with 100 nM Bortezomib (BTZ), a dual LonP1³⁰ and CT-L
372 proteasome inhibitor. In the D-54 MG line, BTZ resulted in decreases in Aco2 levels at 24 h to 0.3-fold;
373 however, it increased TFAM levels by 4-fold. In the U-87 line, BT317 resulted in the accumulation of Aco2
374 gradually to 3-fold and TFAM accumulated by 1.5-fold after 24 h and this effect was similarly mimicked by
375 BTZ with 2.4 and 2.1-fold increase in protein levels, respectively. The LonP1 substrate
376 accumulation/degradation observed exceeded what was expected given that previously demonstrated
377 LonP1 protease inhibition.

378

379 **3.4. BT317 Exhibits Synergy with Temozolomide in Autophagy-Dependent Cell Death in IDH1 Mutant**
380 **Malignant Astrocytoma**

381 Current glioma research and clinical trials emphasize the role of GSCs in tumor maintenance, resistance
382 to therapies, and local invasion⁴⁴. The patient-derived lines are enriched for tumor-initiating cancer stem
383 cells by passaging in serum-free, suspension culture with referenced growth factors and have been shown
384 to recapitulate the expression profile of the original patient sample⁴⁵. Using the XTT assay, we determined

385 the IC₅₀ viability of established and patient-derived GSC lines in response to 72 h of exposure to BT317 at
386 graded doses (**Fig. 4A panel 1**). BT317 had increased toxicity towards the patient-derived GSC lines (i.e.,
387 83MES, DB70, DB76, DB77, DB81; **Supplemental Table 1**) as compared to the established and
388 differentiated astrocytoma lines, consistent with previous research which demonstrated that GSC are
389 more sensitive to proteasome and LonP1 inhibition as compared with the more differentiated established
390 lines⁴⁶. The sensitivity of the DB70 line did not differ significantly from the DB81 line, derived from the
391 same patient following recurrence. BT317 also showed less activity towards the CHLA-200 pediatric line
392 (IC₅₀=73.61 μM). The normal cell lines, HPF242 and MCF10A, fibroblasts, and human astrocytes, also
393 exhibited higher viability following treatment with BT317. Furthermore, BT317 synergized with 10 μM
394 TMZ to decrease cell viability in the TMZ-resistant DB70 and DB76 GSC lines (recurrence following TMZ
395 treatment) (**Fig. 4A panel 2, and S4A**). Interestingly, this synergy was not observed in the IDH wildtype
396 lines, DB77 and 83MES (**Fig. 4A panel 3 and S4A**). Co-incubation of 10 μM BT317 with 10 μM TMZ in the
397 DB70 line resulted in a significant increase in ROS by 1.5-fold (**Fig. 4B**). BT317 alone did induce a significant
398 increase in ROS by 1.3-fold at 8 h in the DB70 line; however, only a slight decrease in ROS to 0.78-fold was
399 observed at 4 h following treatment in the 83MES line (**Supplementary Fig. 4C**). The IDH1 mutant lines
400 exhibited increased LC3B-I and II at 1, 12, 24 h post-treatment and this was reversed with co-incubation
401 with 10 μM TMZ. Furthermore, C-MET and FOXM1 levels increased with BT317 or TMZ alone; however,
402 the combination resulted in a decrease in C-MET and FOXM1 levels. This also coincided with a significant
403 increase in Aco2 and TFAM with or without TMZ. The mTOR pathway (e.g., pAKT), which is capable of
404 suppressing autophagy, was also upregulated with TMZ incubation at the earlier timepoints in the DB70
405 line; however, this was less obvious in the DB76 line, where there was a change of 0.57 and 1.83-fold for
406 both bands at 1 h after combinatorial treatment (**Fig. 4C**). In the IDH1 wildtype lines, BT317 also increased
407 LC3B-I, Aco2 and TFAM levels. DB77 showed a spike in LC3B-I levels by 7.62-fold that was reduced to 1.74-
408 fold by 24 h, and demonstrated partial ablation of autophagy induced by co-incubation with TMZ. The
409 83MES line did not show significant induction of autophagy; however, it demonstrated a 2-fold ablation
410 following incubation with TMZ at 24 h. Both BT317 and TMZ resulted in an increase in pAKT levels. In
411 contrast, the DB77 line did exhibit elevated pAKT at 1 h with co-treatment and 24 h with TMZ alone (**Fig.**
412 **4C and S4B**) The more modest increase in pAKT following TMZ treatment could be due in part to the
413 increased resistance to TMZ alone exhibited by the DB76 and DB77 lines – particularly at 10μM TMZ. In
414 the IDH mutant DB76 line, the large autophagic response with BT317 treatment may partly explain its
415 sensitivity to modest activation of mTOR signaling with TMZ treatment (**Supplementary Fig. 4D**). This
416 muted autophagic response highlights the limited autophagy-induced cell death at 25μM BT317 in the
417 DB77 line and the lack of autophagy-dependent cell death in the 83MES line, following co-incubation with
418 3mM 3-methyladenine (3-MA), an autophagy inhibitor. As expected in the IDH1 mutant lines, autophagy-
419 dependent cell death was evident at lower concentrations of BT317 (**Fig. 4D**). Furthermore, the
420 combinatorial treatment resulted in overall reduction in levels of FOXM1 and most significantly by ~2-fold
421 at the 24 h timepoint for DB70 and DB76. This mimics previous observations with the combinatorial
422 treatment of BTZ and TMZ³³. Both DB77 and 83MES showed a relative increase of ~0.2-fold at 24 h. It was
423 previously reported that TMZ targets more differentiated populations with an average IC₅₀ of ~540 μM
424 against similar glioma lines⁴⁷, whereas BT317 offers far greater efficacy against the harder to eradicate
425 GSC populations (**Supplemental Table 1**). Furthermore, these data highlight the potential use of
426 BT317 in combination with TMZ as a treatment modality to target diverse cell populations and potentially
427 to reverse malignant astrocytoma treatment resistance.

428

429 **3.5. BT317 Exhibits Low Toxicity and its Activity is Localized to the Tumor Microenvironment**

430 Previous development of proteasome inhibitors for the treatment of GBM was limited by either poor BBB
431 penetrance (i.e., BTZ)³¹ or by the presence of the central nervous system (i.e., MRZ= marizomib, confusion,
432 ataxia)⁴⁸ or peripheral nervous system (BTZ, peripheral neuropathy)⁴⁹ toxicity. The development of these
433 toxicities is directly related to the level of proteasome inhibition in the blood and in the normal brain⁵⁰.

434 Prior to evaluating efficacy, we established the maximum tolerated dose (MTD). Using a previously
435 established methodology³⁶, we observed the clinical score following treatment (n=2) with iterative 50%
436 dose escalation until we determined the MTD to be >180 mg/kg (data not shown). We repeated a
437 continuous dose series over 10 days with 100 mg/kg of BT317 every other day or daily. There was no
438 noticeable drop in weight or any observable clinical signs (**Fig. 5A**). Next, we administered 100 mg/kg
439 BT317 and 25 mg/kg TMZ or 100 mg/kg BT317 and 50 mg/kg TMZ daily for 10 days. A temporary drop in
440 weight and minor clinical signs were observed following the first 2 doses with 100 mg/kg BT317 and 50
441 mg/kg TMZ; however, the animal weight normalized by day 4 and no further clinical signs were observed.
442 Novel therapeutic candidates for malignant astrocytomas must have superior BBB penetrance, target
443 GSCs, synergize with the standard of care, TMZ, and demonstrate improved survival *in vivo*. To assess BBB
444 penetrance, 9x BALB/c mice received a single intraperitoneal (i.p.) injection of BT317 (3 mg/kg). The
445 animals were euthanized 30, 60, and 120 min post-BT317 injection (n=3 per endpoint). Brain and plasma
446 samples were collected, and BT317 (ng/mL) levels were quantified using mass spectrometry (**Fig. S5A**).
447 BT317 levels reached ~390 ng/mL in the brain at 30 min and decreased to ~55 ng/mL at 120 min post-
448 injection. At all measured endpoints, levels in the brain were significantly higher than those in the plasma.

449 To evaluate the on-site activity of BT317, we performed an intracranial implantation with the DB70 line
450 and after 15 days administered a single dose of 100 mg/kg of BT317 to the mice prior to analyzing
451 proteasome activity in the blood, healthy brain, and intracranial tumor mass (**Fig. 5B**). The animals were
452 euthanized 1 and 4 h post-injection (n=6 per endpoint). BT317 showed ~70% and 60% inhibition of CT-L
453 and C-L activity in the tumor, respectively, compared with ~50% and 25% for MRZ at 4 h. Only MRZ showed
454 CT-L inhibition in the normal healthy brain with a ~40% reduction at 1-4 h. Furthermore, MRZ also
455 inhibited CT-L, T-L, and C-L in the blood by ~90%, 35-45%, and 30%, respectively. BT317 did not inhibit
456 proteasome activity in the blood. Both BT317 and MRZ showed accumulation of Aco2 in the tumor at 4 h
457 with ~60-70% increase on average (**Supplementary Fig. 4**).

458

459 **3.6. BT317 and Combinatorial Treatment with BT317 and TMZ Increases Survival**

460 Next, we assessed the efficacy in an orthotopic xenograft model using the GSC patient-derived, IDH1-
461 R132H DB70 and DB76 lines. Rag1 KO mice were intracranially implanted with DB70 or DB76 (1000
462 cells/mouse), dissociated from a novel *in vitro*, organoid model³⁷ (**Fig. 6**). A total of 5 doses were
463 administered at 100 mg/kg BT317 ± 50 mg/kg TMZ daily, starting 10 days after intracranial xenograft
464 implantation and continuing for a total of 5 days. BT317 alone significantly improved the median survival
465 by 1 (p<0.05) and 3 days (p<0.05) in the DB70 and DB76 xenografts, respectively. The combination of
466 BT317 and TMZ significantly improved overall survival (p<0.01); however, median survival for the
467 combinatorial cohorts could not be determined by the end of the experiment. We also found that earlier
468 dosing regimen starting on day 5 for a total 5 doses of 100 mg/kg BT317 every other day significantly
469 increased median survival from 25 to 33 days in the DB70 PDX model (10,000 cells/mouse, **Supplementary**

470 **Fig. 6A).** The 83MES PDX model also showed a modest increase in median overall survival from 17.5 to 19
471 days; however, this required an escalated dosage of 150 mg/kg BT317 (10,000 cells/mouse,
472 **Supplementary Fig. 6B).**

473

474 **Discussion and Conclusion**

475 Previously, we demonstrated that the LonP1 inhibitor, CC4, was effective against established glioma lines
476 and that proteasome inhibition with marizomib is effective in *in vitro* and *in vivo* glioma models, though
477 its clinical use is limited by significant CNS toxicity⁵¹. Here we have reported on the designing of the novel
478 LonP1 and CT-L proteasome inhibitor, BT317, which has specific activity and limited toxicity.

479 For our rational design and SAR modeling, we used customized computational protein structure modeling
480 programs, as well as standard programs, to identify the lead compounds that could be derived from CC4
481 to improve solubility and BBB permeability and reduce toxicity. For compound design, we used the Lipinski
482 rule of 5 with the following considerations: (1) biological activity (i.e., more sp³ carbon atoms), (2) ease
483 of synthesis, and (3) moderate compound complexity to minimize toxicity and off-target effects⁵².

484 Our lead molecule, BT317, exhibited dual inhibition of LonP1 protease activity and CT-L proteasomal
485 activity, on-target LonP1 inhibition, BBB permeability, low animal toxicity, and prolonged survival with
486 and without the standard-of-care in two patient-derived IDH1-R132H GSC intracranial xenograft models.
487 BT317 accumulated at higher levels in the brain than in the plasma at 30 min post-administration. Its
488 potent dual inhibitory activity can be compared with that of BTZ, a potent proteasome inhibitor that also
489 inhibits LonP1 protease activity. However, BTZ has limited penetrance into the brain, and a phase II clinical
490 trial of BTZ and bevacizumab in recurrent GBM was hindered due to dose-limiting sensory neuropathy
491 associated with BTZ⁵³. Another CT-L proteasome inhibitor tested for GBM was ritonavir. Nonetheless,
492 ritonavir failed to demonstrate efficacy due to the development of resistance, *in vivo*⁵⁴. Marizomib has
493 also shown improved survival in orthotopic GBM models; however, it has exhibited underlying issues with
494 significant CNS toxicity (confusion, ataxia, fatigue)⁵⁵ in phase 2 studies and did not improve survival in a
495 phase 3 randomized clinical trial⁴⁸. This toxicity is represented by the high rate of marizomib-treated
496 patients that have neurologic (67%) and psychiatric (52%) adverse events⁵¹. Additionally, the high MTD
497 and specific tumor activity of BT317 further demonstrate its potential as a less toxic dual LonP1 and
498 proteasomal inhibitor for GBM treatment.

499 GBM is characterized by mitochondrial dysfunction, including metabolic shifts towards aerobic glycolysis,
500 elevated ROS generation, and sensitivity to metabolic stress²². Aconitase participates in the tricarboxylic
501 acid cycle (TCA) by converting citrate to isocitrate; however, its involvement in malignant astrocytoma
502 metabolism is unclear. Recent studies have shown that Aco2 levels are decreased in breast cancer cell
503 lines and patient-derived tumor biopsies, and Aco2 overexpression impairs breast cancer cell proliferation
504 and mitigates the Warburg effect by redirecting pyruvate to the mitochondria⁵⁶. In addition to its role in
505 the TCA cycle, aconitase also promotes mtDNA stability by interacting with nucleoids (protein-mtDNA
506 complexes)⁵⁷. Our findings revealed pronounced Aco2 accumulation in stable GBM lines and patient-
507 derived GSCs following BT317 exposure. Notably, BT317 induced Aco2 accumulation at 10 μ M despite the
508 IC_{50} =56 μ M for LonP1 protease inhibition. This accumulation was more pronounced than that induced by
509 100 nM BTZ, with previously reported LonP1 protease inhibition (IC_{50} =60 nM)³⁰. BT317 also increased
510 Aco2 levels in an intracranial xenograft model. Further investigation of the role of Aco2 in malignant

511 astrocytoma metabolism and how the different BT317 moieties may enhance LonP1 protease inhibition
512 is warranted.

513 An important finding of our study is that the combination of BT317 and TMZ is more effective than BT317
514 or TMZ alone in IDH1-R132H GSC lines DB70 and DB76. The IDH wildtype GBM and astrocytoma cell lines
515 and the normal human fibroblast cell lines, HPF242 and MCF-10A, were less sensitive to combinatorial
516 treatment. Introduction of IDH1-R132H mutation to wildtype gliomas has been observed to increase ROS
517 generation⁵⁸ and decrease HIF1A⁵⁹⁻⁶¹ and NRF2 signaling⁶²; however, this may be due to an altered hypoxic
518 response⁶³ and may also depend on the tumor microenvironment⁵⁹. TMZ has been found to induce mTOR
519 signaling (e.g., pAKT)^{64,65} and also subsequently block autophagy⁶⁵ in the 12-60 h range. This inhibition of
520 autophagy likely explains the strong synergy between TMZ and BT317, as BT317 clearly induces autophagy
521 and blocking autophagy with 3-MA was found to induce cell death. Additionally, the maximum tolerated
522 dose was exceptionally high, with little to no off-target proteasome inhibition. Targeting the GSC
523 population is critical for overcoming glioma treatment resistance. The dependence of GSCs on LonP1 and
524 CT-L proteasome activity is further highlighted by the upregulation of LonP1 in high-grade GSCs compared
525 to low-grade GSCs and neural stem cells (**Supplementary Fig. 2**). Proteasome activity also plays a key role
526 in cancer treatment resistance^{25,26}. Interestingly, gliomas have elevated CT-L proteasome activity and,
527 generally, an increase in this activity serves as a compensatory response to prooxidative treatment⁶⁶.
528 Additional studies are vital to further explore the role of LonP1 and CT-L proteasome activity in malignant
529 glioma metabolism and whether dual inhibition could be useful for treating recurrent malignant
530 astrocytoma based on patient-specific genetic determinants. Future work will also seek to understand the
531 best route of administration, while also creating BT317 analogs that incorporate nanoparticles and other
532 moieties to optimize on-site and on-target activity to further the development of new therapeutic options
533 for malignant astrocytoma patients.

534 3. References

- 535 1. Ohgaki H, Dessen P, Jourde B, et al. Genetic Pathways to Glioblastoma: A Population-Based
536 Study. *Cancer research*. 2004; 64(19):6892-6899.
- 537 2. Sathornsumetee S, Rich JN, Reardon DA. Diagnosis and Treatment of High-Grade Astrocytoma.
538 *Neurologic Clinics*. 2007; 25(4):1111-1139.
- 539 3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant
540 temozolomide for glioblastoma. *N Engl J Med*. 2005; 352(10):987-996.
- 541 4. Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y, Collis SJ. Tumour treating
542 fields therapy for glioblastoma: current advances and future directions. *British Journal of Cancer*.
543 2021; 124(4):697-709.
- 544 5. Fisher JP, Adamson DC. Current FDA-Approved Therapies for High-Grade Malignant Gliomas.
545 *Biomedicines*. 2021; 9(3).
- 546 6. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in
547 glioblastoma. *N Engl J Med*. 2005; 352(10):997-1003.
- 548 7. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. *Clin Cancer Res*.
549 2013; 19(4):764-772.
- 550 8. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central
551 Nervous System: a summary. *Neuro-Oncology*. 2021; 23(8):1231-1251.
- 552 9. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med*. 2009;
553 360(8):765-773.

- 554 **10.** Golub D, Iyengar N, Dogra S, et al. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted
555 Cancer Therapeutics. *Front Oncol.* 2019; 9:417.
- 556 **11.** Liu Y, Lu Y, Celiku O, et al. Targeting IDH1-Mutated Malignancies with NRF2 Blockade. *J Natl*
557 *Cancer Inst.* 2019; 111(10):1033-1041.
- 558 **12.** Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem
559 cells. *Cancer Cell.* 2009; 15(6):501-513.
- 560 **13.** Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: Sibling Rivals for Control of Cancer Cell
561 Metabolism and Proliferation. *Cancer Cell.* 2007; 12(2):108-113.
- 562 **14.** Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene
563 transcription by hypoxia-inducible factor 1. *Molecular and Cellular Biology.* 1996; 16(9):4604-
564 4613.
- 565 **15.** Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-
566 inducible-factor pathway in glioma growth and angiogenesis. *Neuro-oncology.* 2005; 7(2):134-
567 153.
- 568 **16.** Yang L, Lin C, Wang L, Guo H, Wang X. Hypoxia and hypoxia-inducible factors in glioblastoma
569 multiforme progression and therapeutic implications. *Experimental Cell Research.* 2012;
570 318(19):2417-2426.
- 571 **17.** Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome
572 oxidase subunits to optimize efficiency of respiration in hypoxic cells. *Cell.* 2007; 129(1):111-122.
- 573 **18.** Rep M, van Dijl JM, Suda K, Schatz G, Grivell LA, Suzuki CK. Promotion of mitochondrial
574 membrane complex assembly by a proteolytically inactive yeast Lon. *Science (New York, N.Y.).*
575 1996; 274(5284):103-106.
- 576 **19.** Liu T, Lu B, Lee I, Ondrovicova G, Kutejova E, Suzuki CK. DNA and RNA binding by the
577 mitochondrial Lon protease is regulated by nucleotide and protein substrate. *The Journal of*
578 *biological chemistry.* 2004; 279(14):13902-13910.
- 579 **20.** Quiros PM, Espanol Y, Acin-Perez R, et al. ATP-dependent Lon protease controls tumor
580 bioenergetics by reprogramming mitochondrial activity. *Cell Rep.* 2014; 8(2):542-556.
- 581 **21.** Cheng CW, Kuo CY, Fan CC, et al. Overexpression of Lon contributes to survival and aggressive
582 phenotype of cancer cells through mitochondrial complex I-mediated generation of reactive
583 oxygen species. *Cell Death Dis.* 2013; 4:e681.
- 584 **22.** Di K, Lomeli N, Wood SD, Vanderwal CD, Bota DA. Mitochondrial Lon is over-expressed in high-
585 grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in
586 glioma. *Oncotarget.* 2016; 7(47):77457-77467.
- 587 **23.** Bayot A, Basse N, Lee I, et al. Towards the control of intracellular protein turnover:
588 Mitochondrial Lon protease inhibitors versus proteasome inhibitors. *Biochimie.* 2008; 90(2):260-
589 269.
- 590 **24.** Stahlberg H, Kutejová E, Suda K, et al. Mitochondrial Lon of *Saccharomyces*
591 *cerevisiae* is a ring-shaped protease with seven flexible subunits. *Proceedings of the*
592 *National Academy of Sciences.* 1999; 96(12):6787-6790.
- 593 **25.** Adams J. The proteasome: structure, function, and role in the cell. *Cancer Treat Rev.* 2003; 29
594 Suppl 1:3-9.
- 595 **26.** Patel NM, Nozaki S, Shortle NH, et al. Paclitaxel sensitivity of breast cancer cells with
596 constitutively active NF-kappaB is enhanced by I kappa B alpha super-repressor and parthenolide.
597 *Oncogene.* 2000; 19(36):4159-4169.
- 598 **27.** Maneix L, Sweeney MA, Lee S, et al. The Mitochondrial Protease LonP1 Promotes Proteasome
599 Inhibitor Resistance in Multiple Myeloma. *Cancers (Basel).* 2021; 13(4).

- 600 28. Lee J, Pandey AK, Venkatesh S, et al. Inhibition of mitochondrial LonP1 protease by allosteric
601 blockade of ATP binding and hydrolysis via CDDO and its derivatives. *The Journal of biological*
602 *chemistry*. 2022; 298(3):101719.
- 603 29. Gibellini L, Pinti M, Bartolomeo R, et al. Inhibition of Lon protease by triterpenoids alters
604 mitochondria and is associated to cell death in human cancer cells. *Oncotarget*. 2015;
605 6(28):25466-25483.
- 606 30. Csizmadia V, Hales P, Tsu C, et al. Proteasome inhibitors bortezomib and carfilzomib used for the
607 treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi. *Toxicol Res*
608 *(Camb)*. 2016; 5(6):1619-1628.
- 609 31. Takeshima K, Mizuno K, Nakahashi H, Aoki H, Kanekiyo Y. Ratiometric Sensing of Hydrogen
610 Peroxide Utilizing Conformational Change in Fluorescent Boronic Acid Polymers. *Journal of*
611 *Analytical Methods in Chemistry*. 2017; 2017:7829438.
- 612 32. Huehnchen P, Springer A, Kern J, et al. Bortezomib at therapeutic doses poorly passes the
613 blood–brain barrier and does not impair cognition. *Brain Communications*. 2020; 2(1).
- 614 33. Tang JH, Yang L, Chen JX, et al. Bortezomib inhibits growth and sensitizes glioma to
615 temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. *Cancer Commun (Lond)*.
616 2019; 39(1):81.
- 617 34. Seidel S, Garvalov BK, Acker T. Isolation and Culture of Primary Glioblastoma Cells from Human
618 Tumor Specimens. In: Rich IN, ed. *Stem Cell Protocols*. New York, NY: Springer New York;
619 2015:263-275.
- 620 35. Van der Borcht K, Tourny A, Bagdziunas R, et al. BIGL: Biochemically Intuitive Generalized Loewe
621 null model for prediction of the expected combined effect compatible with partial agonism and
622 antagonism. *Sci Rep*. 2017; 7(1):17935.
- 623 36. Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ. A systematic investigation
624 of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in
625 mice. *BMC cancer*. 2017; 17(1):684-684.
- 626 37. Hubert CG, Rivera M, Spangler LC, et al. A Three-Dimensional Organoid Culture System Derived
627 from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell
628 Heterogeneity of Tumors Found In Vivo. *Cancer research*. 2016; 76(8):2465-2477.
- 629 38. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. *Autophagy*. 2007; 3(6):542-
630 545.
- 631 39. Vassallo JD, Hicks SM, Daston GP, Lehman-McKeeman LD. Metabolic Detoxification Determines
632 Species Differences in Coumarin-Induced Hepatotoxicity. *Toxicological Sciences*. 2004;
633 80(2):249-257.
- 634 40. Lassalas P, Gay B, Lasfargeas C, et al. Structure Property Relationships of Carboxylic Acid
635 Isosteres. *Journal of medicinal chemistry*. 2016; 59(7):3183-3203.
- 636 41. Halasi M, Wang M, Chavan Tanmay S, Gaponenko V, Hay N, Gartel Andrei L. ROS inhibitor N-
637 acetyl-L-cysteine antagonizes the activity of proteasome inhibitors. *Biochemical Journal*. 2013;
638 454(2):201-208.
- 639 42. Manton CA, Johnson B, Singh M, Bailey CP, Bouchier-Hayes L, Chandra J. Induction of cell death
640 by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo. *Scientific*
641 *Reports*. 2016; 6(1):18953.
- 642 43. Bota DA, Davies KJ. Lon protease preferentially degrades oxidized mitochondrial aconitase by an
643 ATP-stimulated mechanism. *Nature cell biology*. 2002; 4(9):674-680.
- 644 44. Chen J, Li Y, Yu T-S, et al. A restricted cell population propagates glioblastoma growth after
645 chemotherapy. *Nature*. 2012; 488(7412):522-526.

- 646 45. Vik-Mo EO, Sandberg C, Olstorn H, et al. Brain tumor stem cells maintain overall phenotype and
647 tumorigenicity after in vitro culturing in serum-free conditions. *Neuro Oncol.* 2010; 12(12):1220-
648 1230.
- 649 46. Gong X, Schwartz PH, Linskey ME, Bota DA. Neural stem/progenitors and glioma stem-like cells
650 have differential sensitivity to chemotherapy. *Neurology.* 2011; 76(13):1126-1134.
- 651 47. Ferretti M, Fabbiano C, Di Bari M, et al. M2 receptor activation inhibits cell cycle progression and
652 survival in human glioblastoma cells. *Journal of cellular and molecular medicine.* 2013; 17.
- 653 48. Di K, Lloyd GK, Abraham V, et al. Marizomib activity as a single agent in malignant gliomas:
654 ability to cross the blood-brain barrier. *Neuro-oncology.* 2016; 18(6):840-848.
- 655 49. Rutkowski S, Gerber NU, von Hoff K, et al. Treatment of early childhood medulloblastoma by
656 postoperative chemotherapy and deferred radiotherapy. *Neuro-Oncology.* 2009; 11(2):201-210.
- 657 50. Velasco R, Alberti P, Bruna J, Psimaras D, Argyriou AA. Bortezomib and other proteasome
658 inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment. *Journal of the*
659 *Peripheral Nervous System.* 2019; 24(S2):S52-S62.
- 660 51. Roth P, Gorlia T, Reijneveld JC, et al. EORTC 1709/CCTG CE.8: A phase III trial of marizomib in
661 combination with temozolomide-based radiochemotherapy versus temozolomide-based
662 radiochemotherapy alone in patients with newly diagnosed glioblastoma. Paper presented at:
663 ASCO Annual Meeting2021.
- 664 52. Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to
665 improving clinical success. *Journal of medicinal chemistry.* 2009; 52(21):6752-6756.
- 666 53. Bota DA, Eroglu Z, Reardon DA, et al. Phase II clinical trial of bortezomib and bevacizumab
667 combination in recurrent glioblastoma. *Journal of Clinical Oncology.* 2011; 29(15_suppl):2056-
668 2056.
- 669 54. Laurent N, de Boüard S, Guillamo JS, et al. Effects of the proteasome inhibitor ritonavir on
670 glioma growth in vitro and in vivo. *Mol Cancer Ther.* 2004; 3(2):129-136.
- 671 55. Bota DA, Mason W, Kesari S, et al. Marizomib alone or in combination with bevacizumab in
672 patients with recurrent glioblastoma: Phase I/II clinical trial data. *Neurooncol Adv.* 2021;
673 3(1):vdab142-vdab142.
- 674 56. Ciccarone F, Di Leo L, Lazzarino G, et al. Aconitase 2 inhibits the proliferation of MCF-7 cells
675 promoting mitochondrial oxidative metabolism and ROS/FoxO1-mediated autophagic response.
676 *British Journal of Cancer.* 2020; 122(2):182-193.
- 677 57. Farooq MA, Pracheil TM, Dong Z, Xiao F, Liu Z. Mitochondrial DNA Instability in Cells Lacking
678 Aconitase Correlates with Iron Citrate Toxicity. *Oxidative Medicine and Cellular Longevity.* 2013;
679 2013:493536.
- 680 58. Li LC, Zhang M, Feng YK, Wang XJ. IDH1-R132H Suppresses Glioblastoma Malignancy through
681 FAT1-ROS-HIF-1 α Signaling. *Neurol India.* 2020; 68(5):1050-1058.
- 682 59. Williams SC, Karajannis MA, Chiriboga L, Golfinos JG, von Deimling A, Zagzag D. R132H-mutation
683 of isocitrate dehydrogenase-1 is not sufficient for HIF-1 α upregulation in adult glioma. *Acta*
684 *Neuropathol.* 2011; 121(2):279-281.
- 685 60. Yao J, Chakhoyan A, Nathanson DA, et al. Metabolic characterization of human IDH mutant and
686 wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. *Neuro-Oncology.*
687 2019; 21(9):1184-1196.
- 688 61. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α -
689 Ketoglutarate-Dependent Dioxygenases. *Cancer Cell.* 2011; 19(1):17-30.
- 690 62. Li K, Ouyang L, He M, et al. IDH1 R132H mutation regulates glioma chemosensitivity through
691 Nrf2 pathway. *Oncotarget.* 2017; 8(17):28865-28879.
- 692 63. Dao Trong P, Rösch S, Mairbörl H, et al. Identification of a Prognostic Hypoxia-Associated Gene
693 Set in IDH-Mutant Glioma. *Int J Mol Sci.* 2018; 19(10).


- 694 **64.** Murphy SF, Varghese RT, Lamouille S, et al. Connexin 43 Inhibition Sensitizes Chemoresistant
695 Glioblastoma Cells to Temozolomide. *Cancer research*. 2016; 76(1):139-149.
- 696 **65.** Yu Z, Zhao G, Xie G, et al. Metformin and temozolomide act synergistically to inhibit growth of
697 glioma cells and glioma stem cells in vitro and in vivo. *Oncotarget*. 2015; 6(32):32930-32943.
- 698 **66.** Kretz-Remy C, Arrigo A-P. Modulation of the chymotrypsin-like activity of the 20S proteasome
699 by intracellular redox status: effects of glutathione peroxidase-1 overexpression and antioxidant
700 drugs. *Biol Chem*. 2003; 384(4):589-595.

701


702

703


A CDDO-ME and CFZ Synergy



B CDDO-ME and CFZ Isoblogram



C



D





Figure 1. Dual LonP1 and Chymotrypsin-like Proteasome Inhibition has Greater Synergy in IDH1 Mutant Astrocytoma and Enhances Autophagy and ROS Production. (A) In combination with Carfilzomib, a selective chymotrypsin-like proteasome inhibitor, CDDO-ME, a known LonP1 inhibitor, demonstrates strong synergy at 200nM in IDH1 mutant lines, whereas (B) the IDH1 wildtype lines only show limited synergy at 400-500nM. (C) LC3B levels and (D) ROS levels were assessed following treatment with 5nM CFZ and/or 200nM CDDO-ME at 1, 12 and 24 h timepoints in DB70 and DB76. (E) Similarly ROS levels were analyzed in 83MES. Statistical significance was determined by t-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$; n.s., not significant.

A



B




Figure 2. LonP1 small molecule inhibitor BT317 was derived from CC4. (A) BT317 is an analog of CC4. (B) Synthesis of BT317.




Figure 3. BT317 acts as a dual LonP1 and chymotrypsin-like proteasome inhibitor. (A) BT317 inhibition of LonP1 protease activity was assessed using a FITC-Casein substrate. (B) 10 μ M BT317 or 100nM BTZ were evaluated for proteasome inhibition at 1, 4, 6, 8 h. NAC was used to ablate proteasome inhibition. (C) The IDH1 wildtype U-251 and U-87 MG lines were treated with 10 μ M BT317 and demonstrated increased Aco2 and TFAM levels. Data are presented as mean \pm SEM of at least 3 replicates. Statistical significance was determined by t-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$; n.s., not significant.




Figure 4. BT317 drives autophagy-dependent cell death in specifically IDH1 mutant astrocytoma and TMZ works synergistically by blocking autophagy. (A) Astrocytes, multiple fibroblast lines, established GBM lines (panel 1), IDH1 mutant glioma lines DB70 and DB76 \pm 10 μ M TMZ (panel 2), and IDH1 wildtype glioma lines DB77 and 83MES \pm 10 μ M TMZ (panel 3) were treated with titrated doses of BT317 for 5 days prior to measuring viability. (B) ROS were measured using CellROX Orange at 12 h and (C) protein samples analyzed following incubation with 10 μ M BT317 \pm 10 μ M TMZ at 1, 12 and 24 h as detailed. (D) The IDH1 mutant and wildtype lines were analyzed for autophagy-dependent cell death following treatment with a titer of BT317 and co-incubation with 3mM 3-MA for 5 days. Statistical significance was determined by t-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$; n.s., not significant.




Figure 5. The combination of BT317 and TMZ has minimal toxicity in NSG mice. (A) BT317 was administered at 100mg/kg every other or every day for 10 total days \pm 25 or 50 mg/kg TMZ and weight and clinical score was monitored. (B) 15 days after intracranial implantation of DB70, BT317 (100mg/kg), Marizomib (50 μ g/kg) or DMSO (w/v) were injected i.p. at various doses to proteasome activity and Aco2 levels in the tumor, healthy brain and blood at 1 and 4 h. Statistical significance was determined by t-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$; n.s., not significant.





Figure 6. BT317 and Combinatorial BT317 + TMZ Treatment Significantly Improves Survival. (A) In the DB70 intracranial model, 100 mg/kg BT317 \pm 100 mg/kg TMZ was injected i.p. daily for 5 days starting on day 10 after intracranial implantation. (B) The methodology in (A) was applied to assess any survival advantage in the DB76 intracranial xenograft model. Average weights of animals were tracked from post-implantation for (C) DB70 and (D) DB76. Significance was measured n=3 per endpoint); *p<0.05, **p<0.01, ***p<0.001 ns=not significant. (BT317, n=6; MRZ, n=6, DMSO n=4 per endpoint).


Table 1. Lines for patient-derived samples included in this study.

Patient-derived GSC Lines					
Line	Classification	Grade	IDH1	p53	ATRX
DB70	Astrocytoma	3	Mut	Lost	Lost
DB76	Astrocytoma	4	Mut	Lost	Lost
DB77	Astrocytoma	4	WT	WT	WT
83MES	Glioblastoma	4	WT	N/A	N/A
DB81	Astrocytoma	4	Mut	Lost	Lost


Preprint not peer reviewed




Supplementary Figure S1. LonP1 expression is upregulated in late-stage GBM. (A) LonP1 levels were normalized to B-actin via qPCR for neural stem cells (NSC), low-grade glioma stem cells (LGA-GSC) and glioblastoma glioma stem cells (GBM-GSC). (B) Similarly, LonP1 levels were assessed to determine expression in the established D-54 MG, U-251 MG and GBM-GSC lines.




Supplementary Figure S2. CC4 was also used to derive BT395, BT397 and BT399. Chemical structures are as shown.



Supplementary Figure S3. BT395, BT397 and BT399 Show Limited Inhibition of LonP1 and Proteasome Activity. (A) BT397 was assessed for inhibition of LonP1 protease activity with an IC_{50} established at $58.15\mu M$ (B-D) BT395, BT397 and BT399 have variable levels of short-term proteasome inhibition. NAC= N-acetyl Cysteine; BTZ = Bortezomib; CT-L= Chymotrypsin-like activity; T-L = Trypsin-like activity; C-L = Caspase-like activity. Statistical significance was determined by t-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$; n.s., not significant.




Supplementary Figure S4. BT317 Shows Strong Synergy with TMZ in IDH Mutant GSC Lines. (A) Synergy between BT317 and TMZ was evaluated using BIG, with blue representing significant synergy and red representing antagonism. (B) Protein levels were evaluated at 10 μ M BT317 \pm 10 μ M TMZ for 1-24 h. (C) Relative sensitivity of each GSC line to TMZ. (D) The DB70 line was subjected to 10 μ M BT317 \pm 10 μ M TMZ for 24 h and evaluated for colony forming ability 12 days later. (E) ROS levels were analyzed following BT317 treatment at 1, 4, 9, 12 and 24 h. Statistical significance was determined by t-test. * P < 0.05, ** P < 0.01, *** P < 0.001; n.s., not significant.




C

Liver Tissue Analysis



Supplementary Figure S5. BT317 Shows BBB Permeability, Increased LonP1 Inhibition in the Tumor Xenograft and Limited Liver Toxicity . (A) Following i.p. injection of 3mg/kg BT317, blood and brain samples were assessed via LC-MS for compound levels. (B) Protein levels were evaluated following injection of 100mg/kg of BT317 and 15 days post intracranial xenograft implantation. (C) Liver toxicity was evaluated for gross morphological differences and vein diameter following 100mg/kg of BT317 administered daily for 10 days total. Statistical significance was determined by t-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$; n.s., not significant.



Supplementary Figure S6. BT317 Shows Efficacy Against the 83MES GSC Line. (A) 100 mg/kg in the DB70 or (B) 150 mg/kg BT317 in the 83MES xenograft model was injected i.p. every other day for 5 total doses starting on day 5 after intracranial implantation. Significance was measured n=7 per endpoint).; *p<0.05, **p<0.01, ***p<0.001 ns=not significant. (BT317, n=6; MRZ, n=6, DMSO n=4 per endpoint).